Thus, given the role of local CES2 expression in the activation of irinotecan, direct measurement of CES2 expression and/or activity (rather than TP53 mutational status or p53 protein expression) may be an effective method to predict the efficacy of irinotecan in colorectal cancer. Here, TP53 is linked to colorectal cancer.